Recent advances in cancer therapy-associated oral mucositis

Ragda Abdalla-Aslan, Rebeca Keegan, Yehuda Zadik, Noam Yarom, Sharon Elad*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Oral mucositis (OM) is a common and debilitating toxicity of cancer treatments – chemotherapy, radiotherapy, hematopoietic cell transplant, or combinations. OM is associated with severe oral pain and has negative impacts on patient function and quality of life. Additionally, OM has accompanying systemic complications that may have critical implications. These local and systemic consequences can alter cancer treatment, and add an economic burden. This review covers the clinical presentation and course of OM, differential diagnosis, clinical and economic impacts, pathogenesis, risk factors, assessment measures, biomarkers and prediction of OM, management, research advances in the development of new drugs and treatments, and big data.

Original languageEnglish
JournalOral Diseases
DOIs
StateAccepted/In press - 2024

Bibliographical note

Publisher Copyright:
© 2024 Wiley Periodicals LLC.

Keywords

  • cancer
  • chemotherapy
  • hematopoietic stem cell transplantation
  • mucosal injury
  • oral mucositis
  • radiotherapy

Fingerprint

Dive into the research topics of 'Recent advances in cancer therapy-associated oral mucositis'. Together they form a unique fingerprint.

Cite this